Rabies
MONDO:0019173Rabies is a viral zoonosis leading to a fatal encephalopathy if not treated.
Also known as: lyssa
56 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New Freeze-Dried rabies vaccine aims to save lives in High-Risk regions
⭐️ VACCINE ⭐️ CompletedThis phase 3 trial tests a freeze-dried rabies vaccine in healthy Chinese volunteers aged 10 to 60. The study compares the new vaccine's ability to trigger protective antibodies and its safety against an existing rabies vaccine. Rabies is nearly always fatal once symptoms appear,…
Phase: PHASE3 • Sponsor: Jiangsu Province Centers for Disease Control and Prevention • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 01, 2026 00:00 UTC
-
New vaccines for yellow fever and rabies enter first human tests
⭐️ VACCINE ⭐️ CompletedThis early-stage trial tested two new vaccines—one for yellow fever and one for rabies—in 112 healthy adults aged 18 to 40. The main goal was to check safety and see how well the vaccines trigger an immune response. Participants received different doses or a placebo to help find …
Phase: PHASE1 • Sponsor: AstriVax Therapeutics • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
-
New rabies vaccine schedule tested in 2,000 volunteers
⭐️ VACCINE ⭐️ CompletedThis study tested a new rabies vaccine given in different schedules after exposure. It involved 2,040 healthy people aged 10-60. The goal was to see if the vaccine triggers a strong immune response and is safe compared to a standard vaccine.
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:12 UTC
-
New rabies vaccine shows promise in large thai trial
⭐️ VACCINE ⭐️ CompletedThis Phase 3 trial tested a new rabies vaccine called VRVg-2 in 403 healthy volunteers in Thailand. The study compared two different vaccination schedules and also looked at combining the vaccine with rabies antibodies (immunoglobulins). The goal was to see if the new vaccine pro…
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 18:58 UTC
-
New rabies vaccine passes first safety check in small trial
Disease control CompletedThis early-stage trial tested the safety of a new rabies vaccine in 80 healthy people aged 10 to 60. Participants received one of two different vaccination schedules. Researchers monitored for side effects for up to 6 months. The goal was to see if the vaccine is safe enough to m…
Phase: PHASE1 • Sponsor: Ab&B Bio-tech Co., Ltd.JS • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Rural patients get Hospital-Level care at home in landmark trial
Disease control CompletedThis study looked at whether giving hospital-level care to acutely ill adults in their own homes in rural areas works well. 160 people with various conditions like infections, heart failure, or COPD took part. The goal was to see if this approach could lower costs and help patien…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New rapid test for infection and inflammation put to the test
Diagnosis CompletedThis study looked at how well a new, quick finger-prick test (LumiraDx CRP) measures CRP levels compared to a standard lab test. CRP is a marker of infection, inflammation, or tissue injury. 79 adults with symptoms of these conditions took part. The goal was to see if the new tes…
Sponsor: LumiraDx UK Limited • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New PET scan technique aims to sniff out hidden infections
Diagnosis CompletedThis early study tested whether a special PET scan using a radioactive form of vitamin B9 (11C-PABA) can help doctors see infections deep inside the body. Researchers scanned 13 healthy people and patients with known or suspected infections. The goal was to see if this method can…
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
New rabies shot shows promise in preventing deadly infection after bites
Prevention CompletedThis study tested a new medicine called SYN023 to prevent rabies in people who were bitten or scratched by animals like dogs or bats. About 448 adults with different levels of rabies risk received either SYN023 or the standard rabies immune globulin, along with the rabies vaccine…
Phase: PHASE2 • Sponsor: Synermore Biologics Co., Ltd. • Aim: Prevention
Last updated Jul 01, 2026 00:00 UTC
-
Rabies shot under the skin: could it work?
Prevention CompletedThis study looked at whether a rabies vaccine (RabAvert) can be given just under the skin instead of into a muscle. Researchers tested it in 130 adults, some who had never been vaccinated and some who had. The goal was to see if the skin shot triggers enough protection and is saf…
Phase: NA • Sponsor: Centers for Disease Control and Prevention • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
New rabies vaccine shows promise in large trial
Prevention CompletedThis Phase 3 trial tested a new rabies vaccine (VRVg-2) in 1708 healthy children and adults in Thailand. The goal was to see if it works as well as two existing rabies vaccines when given before exposure to the virus. Participants received a series of shots, and some got a booste…
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Jun 27, 2026 09:03 UTC
-
New rabies antibody shot tested in kids – could replace current treatment?
Prevention CompletedThis study tested a new combination of lab-made antibodies (SYN023) given alongside the rabies vaccine to healthy children under 18. The goal was to see if it is safe and how well it works compared to the standard treatment. A total of 108 children received either a low or high d…
Phase: PHASE1 • Sponsor: Synermore Biologics (Suzhou) Co., Ltd. • Aim: Prevention
Last updated Jun 27, 2026 08:11 UTC
-
New rabies vaccine shows promise in preventing deadly infection
Prevention CompletedThis Phase 3 trial tested a new rabies vaccine (VRVg-2) in 201 healthy adults in Thailand. Participants received the vaccine along with rabies antibodies, mimicking post-exposure treatment. The study measured immune response and safety, finding that the vaccine triggered protecti…
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Jun 26, 2026 18:49 UTC
-
Promising new rabies vaccine passes phase 3 test
Prevention CompletedThis phase 3 trial tested a new rabies vaccine (VRVg-2) in 640 healthy adults in France. Participants received the vaccine along with rabies immune globulin, mimicking a real post-exposure scenario. The study found that VRVg-2 produced protective antibody levels as effectively as…
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Jun 26, 2026 17:51 UTC
-
Rabies vaccine study seeks to sharpen prevention strategies
Knowledge-focused CompletedThis completed early-phase study looked at how healthy adults respond to the rabies vaccine when given alone or with an immune-boosting shot (rabies immune globulin). Thirty participants received different combinations of vaccine and immune globulin to compare antibody levels ove…
Phase: EARLY_PHASE1 • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Are egyptian doctors missing the mark on rabies prevention?
Knowledge-focused CompletedThis completed study surveyed 214 Egyptian doctors—emergency physicians, general practitioners, and surgeons—to see how closely they follow official guidelines for rabies prevention after animal bites. Doctors answered 10 case-based questions, and their scores showed how well the…
Sponsor: Tanta University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
ICU antibiotic dosing: what really matters?
Knowledge-focused CompletedThis study looked at 156 critically ill patients to find out what factors help achieve the right levels of beta-lactam antibiotics in the blood. Researchers collected clinical data and used therapeutic drug monitoring to see which patients reached target concentrations. The goal …
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC